EMILIO ÁLVAREZ FERNÁNDEZ-rekin lankidetzan egindako argitalpenak (6)

2016

  1. Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, Núm. 8, pp. 1444-1452

2015

  1. Human cytomegalovirus and Epstein-Barr virus infection impact on 18F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Núm. 2, pp. 186-196

2013

  1. 18F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: A prospective validation of long-term outcomes

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 40, Núm. 5, pp. 657-667

  2. Clinical significance of VEGFR-2 and 18F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 40, Núm. 11, pp. 1635-1644

2010

  1. 18F-FDG PET bio-metabolic monitoring of neoadjuvant therapy effects in rectal cancer: Focus on nodal disease characteristics

    Radiotherapy and Oncology, Vol. 97, Núm. 2, pp. 212-216

2004

  1. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation

    International Journal of Radiation Oncology Biology Physics